SWEDRES | SVARM Consumption of antibiotics and occurrence of antibiotic resistance in Sweden 2018
SWEDRES|SVARMConsumption of antibiotics and occurrence
of antibiotic resistance in Sweden
2018
SWEDRES |SVARM 20182
A report on Swedish Antibiotic Utilisation and Resistance in Human Medicine (Swedres) and Swedish Veterinary Antibiotic Resistance Monitoring (Svarm)
Published by:Public Health Agency of Sweden and National Veterinary Institute
Editors:Olov Aspevall and Ulrica Dohnhammar, Public Health Agency of Sweden Oskar Nilsson and Märit Pringle, National Veterinary Institute
Addresses:The Public Health Agency of SwedenSolna. SE-171 82 Solna, SwedenÖstersund. Box 505, SE-831 26 Östersund, SwedenPhone: +46 (0) 10 205 20 00Fax: +46 (0) 8 32 83 30 E-mail: [email protected]
National Veterinary InstituteSE-751 89 Uppsala, SwedenPhone: +46 (0) 18 67 40 00Fax: +46 (0) 18 30 91 62E-mail: [email protected]
Text and tables may be cited and reprinted only with reference to this report. Images, photographs and illustrations are pro-tected by copyright.
Suggested citation:Swedres-Svarm 2018. Consumption of antibiotics and occur-rence of resistance in Sweden. Solna/Uppsala ISSN1650-6332
ISSN 1650-6332Article no. 18092This title and previous Swedres and Svarm reports are available for downloading at www.folkhalsomyndigheten.se/publicerat-material/ or at www.sva.se/swedres-svarm/
Layout: Dsign Grafisk Form, Helen Eriksson ABPrint: Taberg Media Group, Taberg 2019Cover by Ingvar Westerdahl/Thomas Isaksson
Scan the QR code to open Swedres-Svarm 2018 as a pdf in your mobile device, for reading and sharing.
Download a free QR code reader in the App Store for Apple devices or in Google Play for Android, for example Quick Scan QR Code Reader (iPhone) or QR Droid Code Scanner (Android).
SWEDRES |SVARM 2018 3
Johan Carlson
Director General
The Public Health Agency of Sweden
Jens Mattsson
Director General
National Veterinary Institute
This report from the monitoring of antibiotic resistance and antibiotic consumption in human and veterinary medicine, Swedres-Svarm, is an integrated report from the Public Health Agency of Sweden and the National Veterinary Institute with data from humans, animals, and food. This collaboration between the public health and veterinary sectors started in 2002.
The term global village was coined already during the 1960:s to describe the phenomenon of our world becoming more interconnected. Since then the term has been more popularised and is also sometimes used to describe our inter-dependence when it comes to antibiotic resistance: we are all in this together and geographic distance is no fail-proof protection. The best way to meet the challenge from wide-spread antibiotic resistance is through a one health approach. This means that we acknowledge the interconnection between people, animals, plants, and our shared environment and that we have a collaborative, multisectoral, and transdisciplinary approach to combat antibiotic resistance. This has also been the theme for the UN Interagency Coordination Group (IACG) on antibiotic resistance. The IACG’s mandate is to provide practical guidance for approaches needed to ensure sustained effective global action to address antibiotic resist-ance. In doing so, IACG has put forward a set of recommen-dations to combat antibiotic resistance that was presented to the United Nations Secretary-General in a report published in April 2019.
The IACG was set up in response to the political declaration on antibiotic resistance made at the UN general assembly in 2016. The group is made up of representatives from the major UN and multi-sectoral agencies and a similar number of indi-
vidual experts. It is co-chaired by the UN Deputy Secretary-General and WHO Director-General. The secretariat is hosted by WHO, with input from the Food and Agricultural Organisation of UN (FAO) and the World Organisation for Animal Health (OIE).
An integral part of any recommendations to combat antibi-otic resistance and work towards a more prudent use of anti-biotics is surveillance and monitoring systems. In this report we can show how the number of ESBL-forming Escherichia coli among poultry has been dropping substantially in Sweden. This is a consequence of our surveillance but would not have happened without close collaboration between authori-ties, farmers, trade organisations and individual companies. Collaboration is also something that Sweden emphasises in its response to IACG, if we want to push for a transforma-tive change on how we combat antibiotic resistance we must engage with all stakeholders including across the agricultural sectors.
In the human sector, the national average for antibiotic prescription is now below 300 prescriptions per 1 000 inhab-itants per year, which is a historically low level. This was accomplished through years of intensive work with antimi-crobial stewardship lead by the regional and national Strama groups. Despite the comparatively good situation in Sweden regarding antibiotic resistance and antibiotic consumption, the preventive work needs to be continued and improved. Recent outbreaks of VRE in hospitals, and an increasing level of resistance to third generation cephalosporins in E. coli caus-ing serious infections are two examples of development in this field that emphasise the need for further action.
Preface
SWEDRES |SVARM 20184
Contributors and participants
EditorsOlov Aspevall and Ulrica Dohnhammar, Public Health Agency of SwedenOskar Nilsson and Märit Pringle, National Veterinary Institute, Sweden
Project ManagerHanna Billström, Public Health Agency of Sweden
Authors SwedresPublic Health Agency of Sweden Olov Aspevall, Hanna Billström, Jessica Darenberg, Ulrica Dohnhammar, Petra Edquist, Hans Gaines, Sara Hæggman, Jenny Hellman, Jerker Jonsson, Sonja Löfmark, Eva Morfeldt, Barbro Mäkitalo, Kristina Rizzardi, Jacqueline Själin, Gunilla Skoog Ståhlgren, Tomas Söderblom, and Thomas Åkerlund
Medical Products Agency Sahra Barzi
Department of Clinical Microbiology, Karolinska University Hospital, Stockholm Christian Giske
Department of Clinical Microbiology, Umeå University, and the Department of infection prevention and control, Region Västerbotten. Anders Johansson
Department of Communicable Disease Control and Prevention, Gävleborg County CouncilSignar Mäkitalo
Department of Communicable Disease Control and Prevention, Stockholm County CouncilOwe Källman, Annie Velander, and Anna Hammarin
Department of Infection Prevention and Control, Region SörmlandMikael Stenhem
Department of Infection Prevention and Control, Stockholm County CouncilSusanne Stiernstedt
Department of Infection Prevention and Control, Örebro University HospitalCharlotta Hellbacher
National Reference laboratory for Antibiotic Resistance, Växjö Hospital Gunnar Kahlmeter
National Reference Laboratory for Sexually Transmitted Infections & National Reference Laboratory for Neisseria meningitidisMagnus Unemo, Hans Fredlund and Susanne Jacobsson
Authors SvarmNational Veterinary Institute Björn Bengtsson, Karin Bergström, Helle Ericsson Unnerstad, Christina Greko, Annica Landén, Oskar Nilsson and Märit Pringle
National Food Agency Maria Egervärn and Catarina Flink
Swedish Board of Agriculture Kinfe Girma
Other contributors in SvarmNational Veterinary Institute Stefan Börjesson, Boel Harbom, Mattias Myrenås and Eva Säker
Farm & Animal HealthMaria Lindberg
Acknowledgements Contributions to SwedresThe analysis of data was made in collaboration with: Annika Hahlin, Mikael Hoffmann, Gunnar Kahlmeter, Christer Norman, Eva Pettersson, and Christina Åhrén.
Data on the sales of antibiotics to acute care hospitals from 2014-2018 was kindly provided by pharmacists in local Strama-groups.
The national surveillance of antibiotic resistance would not have been possible without the contribution of data and active support of all the Swedish clinical microbiology laboratories.
Epidemiological information on clinical notifications checked and updated by the County Departments for Communicable Disease Control.
Contributions to SvarmThank you to Kerstin Ortman and Hanna Arosenius at Animalycen, Skara for kindly providing SVA with clinical isolates and susceptibility results from clinical submissions from animals.
Thank you also to environmental departments in several municipalities for collecting samples of fresh meat from retail for ESBL-screening.
SWEDRES |SVARM 2018 5
Content
Preface ................................................................................... 3Contributors and participants ............................................... 4Sammanfattning/Summary ................................................... 7Guidance for readers ........................................................... 13
Consumption of antibiotics in humans ������������������������������17 Total consumption of antibiotics in humans .................. 17 Antibiotics in outpatient care ......................................... 18 Antibiotics in dentistry .............................................. 26 Antibiotics in hospital care ............................................. 27 Adverse reactions related to antibiotic use ..................... 29 In Focus New DDDs for antibiotics ............................... 30 In Focus IMPACT – a One Health collaboration on antibiotic resistance for sustainable change .............. 32
Sales of antibiotics for animals ������������������������������������������34 Brief on data sources and methodology ......................... 34 Completeness of data ...................................................... 34 Trends in animal populations ......................................... 34 Overall sales .................................................................... 35
Antibiotic resistance in humans ����������������������������������������36 Overview of surveillance systems ................................... 36
In Focus National reference laboratories for antibiotic resistance in humans in Sweden .................... 38
Overview of sampling and culture results ...................... 41 Overview of mandatory
reported antibiotic resistance ......................................... 42 Escherichia coli, Klebsiella pneumoniae, and Enterobacteriaceae with ESBL and ESBLCARBA ............. 43 Staphylococcus aureus including MRSA ............................ 48 Enterococcus faecalis and
Enterococcus faecium including VRE ................................ 51 Streptococcus pneumoniae including PNSP ....................... 53 In Focus Reocurring outbreaks of vancomycin
resistant enterococci in Swedish hospitals ..................... 54 Haemophilus influenzae .................................................... 57 Pseudomonas aeruginosa .................................................... 58 Acinetobacter spp .............................................................. 58 Streptococcus pyogenes ........................................................ 59 Streptococcus agalactiae ...................................................... 59 Mycobacterium tuberculosis ................................................ 60 Neisseria gonorrhoeae ........................................................ 61 Neisseria meningitidis ....................................................... 62 Clostridioides difficile ......................................................... 62 Zoonotic pathogens: Campylobacter and Salmonella .......................................... 63
Antibiotic resistance in animals ����������������������������������������65 Notifiable diseases .......................................................... 65 ESBL-producing Enterobacteriaceae ....................... 65
In Focus ESBL-producing E. coli in meat from lamb on the Swedish market .................... 68
Methicillin-resistant Staphylococcus aureus (MRSA) ..................................... 70 Methicillin-resistant
Staphylococcus pseudintermedius (MRSP) ..................... 73 Zoonotic pathogens ........................................................ 74 Salmonella ................................................................... 74 Campylobacter ..............................................................78 Clinical isolates from animals ......................................... 79 Pigs ............................................................................. 79 Cattle .......................................................................... 82 Laying hens ................................................................ 85 Farmed fish ................................................................ 86 Horses ........................................................................ 86 Dogs ........................................................................... 89 Cats ............................................................................ 92 Indicator bacteria from animals ..................................... 94 Escherichia coli ............................................................. 94
Comparative analysis �����������������������������������������������������������96 Comparison of antibiotic consumption
in human and veterinary medicine ................................. 96 Comparison of antibiotic resistance in human and veterinary medicine ................................. 97 ESBL-producing Enterobacteriaceae ....................... 97 MRSA ......................................................................... 97 MRSP ......................................................................... 98 VRE ............................................................................ 98 Salmonella ................................................................... 98 Campylobacter .............................................................. 98 Clinical resistance in Escherichia coli .......................... 99
Background data, material, methods and references ����101 Demographics and denominator data .......................... 101
Materials and methods, consumption of antibiotics ............................................ 106 Materials and methods, resistance in bacteria from animals .............................. 109 Svarm 2000–2018 ......................................................... 114 References ..................................................................... 117
SWEDRES |SVARM 20186
SWEDRES |SVARM 2018 7
Sammanfattning/Summary
Sammanfattning
När det gäller antibiotikaresistens hos bakterier från männis-kor och djur har Sverige fortfarande en gynnsam situation vid en internationell jämförelse. Detta stöder att vi har effek-tiva strategier för att främja rationell användning av antibio-tika och begränsa spridningen av antibiotikaresistens. Trots vårt jämförelsevis goda läge finns det problem med smitt-spridning och ökande antibiotikaresistens som motiverar fort-satta ansträngningar inom förebyggande arbete. Ett viktigt exempel är de återkommande utbrotten av vankomycinresi-stenta enterokocker på sjukhus. Detta beskrivs närmare i ett In Focus-avsnitt i denna Swedres-Svarm-rapport.
Antibiotikaanvändningen i Sverige har under de senaste årtiondena minskat inom både humanmedicin och veteri-närmedicin. Dessutom har användningen av bredspektrum-antibiotika minskat till fördel för antibiotika med smalare spektrum. Trots det har flera av de typer av resistens som övervakas ökat genom åren. Vissa undantag till dessa nega-tiva trender finns dock.
Viktiga fynd 2018
• Två regioner nådde det nationella målet för antibiotikaför-skrivning till människor på 250 recept per tusen invånare och år; Jämtland och Västerbotten. Detta långsiktiga mål är ett verktyg för att minska onödig antibiotikaanvändning.
• Det nationella genomsnittet för antibiotikaförskrivning till människor har nu nått under 300 recept per tusen invånare och år, vilket är en historiskt låg siffra.
• Ett stort och ett flertal mindre VRE-utbrott på sjukhus. VRE drabbar oftast känsliga patientgrupper där använd-ningen av antibiotika är hög. Under året orsakade en utbrottsstam av VRE blodförgiftning hos fem patienter.
• Hög resistens mot ciprofloxacin hos Escherichia coli och Klebsiella pneumoniae, både från urin och blod från människor. Ciprofloxacin används vid behandling av febril urinvägsinfektion, det är viktigt att ta hänsyn till den höga resistensen vid empirisk behandling.
• Resistensen hos E. coli mot mecillinam och nitrofurantoin, förstahandsmedel vid okomplicerad urinvägsinfektion, är fortfarande låg, fyra respektive en procent.
• Höga nivåer av resistens hos Streptococcus agalactiae (GBS) mot erytromycin och klindamycin. Dessa antibio-tika är alternativ till penicillin vid allergi. Barn kan drabbas av allvarliga infektioner i nyföddhetsperioden orsakade av S. agalactiae.
• Ökande antal fall av Enterobacteriaceae med ESBLCARBA. De är extremt resistenta och det finns få behandlingsal-ternativ vid en eventuell infektion. Tidigt upptäckt och förhindrande av smittspridning inom humansjukvården är därför viktigt.
• Förbrukningen av antibiotika till djur är stabilt låg och domineras av penicillin med smalt spektrum.
• MRSA är ovanliga hos både lantbrukets djur och sällskaps-djur.
• Förekomsten av ESBL-bildande E. coli i tarm- och kött-prov från slaktkyckling har minskat signifikant gentemot tidigare år.
• Bakterier som bildar ESBLCARBA har inte påvisats hos djur i Sverige.
Förbrukning av antibiotika
Antibiotikaförbrukning inom humanmedicinDen totala antibiotikaförbrukningen i Sverige minskade med 4,4 procent mellan 2017 och 2018, till en nivå av 11,7 DDD per tusen invånare och dag. Detta mått omfattar anti-biotika som sålts på recept till enskilda individer och anti-biotika som ges till personer på olika vårdinrättningar såsom sjukhus, ungdomsmottagningar och särskilda boenden. För Region Dalarna ingår enbart den antibiotika som förskri-vits på recept, eftersom regionen inte levererat statistik över försäljning till slutenvården under 2018. Sedan år 2000 har försäljningen av antibiotika i Sverige sjunkit med omkring 19 procent.
Öppenvård
Den minskade försäljningen av antibiotika på recept till patienter i öppenvården under 2018 omfattar de flesta antibiotikaklasser förutom betalaktamasstabila penicilliner (J01CF), trimetoprim med sulfonamid (J01EE) och nitrofu-rantoin (J01XE). Återkommande problem med tillgänglig-het till antibiotika, dels till följd av restnotering av bered-ningar för oral suspension av amoxicillin med klavulansyra respektive cefadroxil, dels efter avregistreringen av ceftibu-ten under år 2017, kan bidra till den minskade försäljningen av kombinationer av penicilliner (J01CR) och cefalosporiner (J01DB-DE).
Antalet recept per tusen invånare i Sverige under 2018 var 296. Detta är en historiskt låg siffra, och den första gången sedan nationell övervakning av antibiotikaförrsäljningen star-tade som den nationella nivån varit under 300. För att nå det nationella målet på 250 recept per tusen invånare och år behövs dock ytterligare minskningar. Två regioner nådde målet under 2018.
Sjukhus och andra vårdformer
Under 2018 var försäljningen av antibiotika på rekvisition något lägre än under 2017, och det nationella medelvärdet är nu 1,52 DDD per tusen invånare och dag. Denna siffra omfattar försäljning av antibiotika som används till patienter på sjukhus samt sådan antibiotika som beställs till läkeme-delsförråd på särskilda boenden och liknande inrättningar.
SWEDRES |SVARM 20188
Data från akutsjukhus visar en något högre antibiotika-försäljning 2018 jämfört med 2017, mätt som både DDD per hundra vårddagar och DDD per hundra vårdtillfällen. Betalaktamasstabila penicilliner (J01CF) fortsätter att vara den största anitbiotikaklassen mätt i antalet DDD. Det är stora skillnader mellan olika regioner, exempelvis vad gäller smalspektrumpenicilliner som utgör mellan omkring 6 och 18 procent av antibiotikaförsäljningen till akutsjukhusen mätt i DDD. Användningen av bredspektrumpreparat – cefalo-sporiner (J01DB-DE), karbapenemer (J01DH), fluoro kino-loner (J01MA) och piperacillin med tazobactam (J01CR05) – visar stora regionala variationer i vilka preparat som används även om den sammanlagda nivån är lika.
Antibiotikaförbrukning inom veterinärmedicinDen rapporterade försäljningen av antibiotika för djur upp gick 2018 till 10 042 kilogram varav 58 procent var penicillin med smalt spektrum. Motsvarande värden för 2009 var 15 368 kilo-gram och 50 procent.
Den totala försäljningen av antibiotika för djur har mins-kat med cirka två tredjedelar sedan 1986 då användningen av tillväxtbefrämjande antibiotika upphörde, korrigerat för att antalet av vissa djurarter har minskat över tid. Under 90-talet minskade användningen av antibiotika som läkeme-del till hela djurgrupper, och under det senaste decenniet ses också en minskad användning av antibiotika för behandling av enskilda djur.
Jämförelse av försäljning inom human- och veterinärmedicinUnder 2018 såldes 59,5 respektive 10,0 ton antibiotika för allmänbehandling inom human- och veterinärmedicin. Mätt som milligram aktiv substans per skattad kilogram biomassa var förbrukningen 88,6 respektive 12,7 milligram per kilo-gram. Försäljning inom humanmedicin dominerade för alla inkluderade antibiotikaklasser utom för trimetoprim-sulfa.
Anmälningspliktig resistens
ESBL-producerande EnterobacteriaceaeESBL-producerande Enterobacteriaceae hos människor har varit anmälningspliktigt sedan 2007. Det är den vanligaste av de anmälningspliktiga resistenstyperna.
Resultat 2018, Enterobacteriaceae med ESBL
• Antal rapporterade fall: 10 341 (föregående år 10 084), rela-tiv förändring +2,5 procent.
• Antal fall med blodförgiftning: 703 (föregående år 594), relativ förändring +18 procent.
• Som tidigare år var Escherichia coli den vanligaste arten, 87 procent, följt av Klebsiella pneumoniae, 9 procent.
Resultat 2018, Enterobacteriaceae med ESBLCARBA• Antal rapporterade fall: 144 (föregående år 116), relativ för -
ändring +24 procent.• Antal fall med blodförgiftning: 7 (föregående år 2).• Även bland Enterobacteriaceae med ESBLCARBA var
E. coli den vanligaste arten, 60 procent, följt av K. pneu-moniae, 33 procent.
Bakterier som bildar ESBL är inte anmälningspliktigt vid fynd hos djur. Sådana bakterier är, med undantag för slakt-kycklingar, ovanliga hos djur i Sverige. Under 2018 under-söktes förekomsten av ESBL-bildande E. coli i tarm- och köttprov från slaktkyckling samt i tarmprov från kalkon och nötkreatur under ett år med selektiva metoder. Sådana bakte-rier hittades i 13 procent av tarmproven från slaktkyckling och i 12 procent av köttproven med svenskt ursprung. Detta innebär en signifikant minskad förekomst gentemot tidigare år. Bakterier som bildar ESBLCARBA har inte påvisats hos djur i Sverige.
Staphylococcus aureus resistenta mot methicillin (MRSA)Samhällsförvärvad smitta är sedan länge den vanligaste typen hos människor, med mer än två tredjedelar av fallen. 2015 delades den upp i familje-/hushållssmitta och samhällsförvär-vad smitta. Familje-/hushållssmitta utgjorde 39 procent av fallen under 2018.
Resultat 2018
• Antal rapporterade fall: 3 864 (föregående år 3 735), relativ förändring +3,5 procent.
• Antal fall med blodförgiftning: 64 (föregående år 55), rela-tiv förändring +16 procent.
• Ett trettiotal mindre smittspridningar inom vård och om sorg rapporterades.
Förekomsten av MRSA hos djur i Sverige är fortfarande låg, vilket begränsar risken för spridning till människor. Under året isolerades MRSA sporadiskt från djurslagen hund, häst och katt. MRSA med mecC påvisades, inom ramen för ett forskningsprojekt, hos igelkott. Hos hundar och katter domi-nerar samma typer av MRSA som hos människor, vilket tyder på att människor är smittkällan. Hos hästar är lantbruksdjurs-typen MRSA CC398 vanligast.
MRSPUnder 2018 var antalet anmälde fall av meticillinresistenta Staphylococcus pseudintermedius (MRSP) hos djur på samma nivå som de senaste åren. Totalt anmäldes 57 fall av MRSP (56 från hund och 1 från katt) till Jordbruksverket. De första åren efter att MRSP hade hittats hos djur i Sverige var i prin-cip alla fall av en viss sekvenstyp (ST71). Numera förekom-mer dock ett flertal olika sekvenstyper och ST71 förekom-mer i princip inte alls.
MRSP är inte anmälningspliktig vid förekomst hos människa.
Streptococcus pneumoniae med nedsatt känslighet för penicillin (PNSP)
Resultat 2018
• Antal rapporterade fall: 91 (föregående år 61), relativ för- ändring +50 procent.
• Antal fall med blodförgiftning: 3 (föregående år 5).• Ett utbrott på förskolor rapporterades från Örebro, det
omfattade 18 fall.
SWEDRES |SVARM 2018 9
Enterococcus faecium och faecalis resistenta mot vankomycin (VRE)
Resultat 2018
• Totalt rapporterades 444 fall: (föregående år 244), relativ förändring +82 procent.
• Antal rapporterade fall av E. faecium med vankomycin-resistens: 438 (föregående år 236), relativ förändring +54 procent.
• Antal rapporterade fall (av E. faecalis): 6 (föregående år 8).• Antal fall av VRE med blodförgiftning 9 (föregående år 2).• Nitton sjukhusrelaterade utbrott rapporterades under året.
Ett större (261 fall), tre mindre med 5-15 fall vardera, övriga var små spridningar med 2-4 fall vardera.
Resistens hos zoonotiska smittämnen
Salmonella är ovanligt hos djur i Sverige och isolerade stam-mar är oftast känsliga för antibiotika. Överförbar resistens mot tredje generationens cefalosporiner har aldrig påvisats hos isolat från djur i Sverige, och resistens mot antibiotika-gruppen fluorokinoloner är mycket ovanlig. För Salmonella-arter var resistensen bland isolat från människor högst mot kinoloner, 22%. Ingen resistens mot meropenem rapporte-rades. Salmonella från svenska djur är en osannolik källa till invasiva infektioner hos människor. För det första rör det sig vanligen om olika typer av stammar, och för det andra är kinolonresistens vanlig hos isolat från människor till skillnad från isolat från djur.
Campylobacter-stammar från djur i Sverige är oftast käns-liga för relevanta antibiotika och exempelvis är resistens mot erytromycin mycket ovanligt. Hos Campylobacter jejuni från människor var resistensen mot ciprofloxacin 50 procent och mot tetracyklin 31 procent 2018. En procent var resistenta mot erythromycin.
Vanligtvis behandlas inte infektioner som orsakas av Sal monella eller Campylobacter med antibiotika, varken hos människor eller hos djur. Hos människa resistensbe-stäms därför endast en liten andel av isolaten, varav de flesta gäller allvarliga infektioner. Se vidare avsnittet ”Comparative ana lysis” för respektive bakterie.
Resistens hos kliniska isolat från människor
All data för dessa sammanställningar samlas in automatiserat via Svebar, ett samarbete mellan de kliniska laboratorierna och Folkhälsomyndigheten.• E. coli: Resistens hos blodisolat mot cefotaxim och cefta-
zidim var 7-8 procent, att jämföra med antalet anmäl-ningar av E. coli ESBL från blod 2018: 470. Resistens mot ciprofloxacin är nu 18 respektive 12 procent hos isolat från blod respektive urin, ett observandum vid val av empirisk behandling av febril urinvägsinfektion.
• K. pneumoniae: Resistens hos blodisolat mot ccefotaxim och ceftazidim var 5 procent, att jämföra med antalet anmälningar av K. pneumoniae ESBL från blod 2018: 66. Liksom för E. coli är resistens mot ciprofloxacin nu relativt hög, 10-11 procent hos isolat från blod och urin.
• Resistensen hos E. coli mot mecillinam och nitrofurantoin, försthandsmedel vid okomplicerad urinvägsinfektion, är fortfarande låg, fyra respektive en procent.
• Staphylococcus aureus: Resistens mot cefoxitin (som indi-kerar MRSA) hos isolat från blod och prover från hud- och mjukdelar var 1,9 procent, att jämföra med antalet anmäl-ningar av MRSA från blod 2018: 64.
• S. agalactiae (GBS): Resistens mot erytromycin och klinda-mycin har gradvis ökat och är nu cirka 20 procent för vart och ett av dessa antibiotika hos isolat från blod.
• Clostridioides difficile: Incidensen har minskat med 25 procent från 2009 till 2016 och därefter varit oförändrad. I likhet med tidigare år var alla undersökta isolat känsliga för metronidazol och vankomycin.
Resistens hos kliniska isolat från djur
Bakterier som orsakar sjukdom hos djur är fortfarande oftast känsliga för de antibiotika som vanligen används. Till exem-pel är bakterier som orsakar luftvägsinfektioner hos lantbru-kets djur och hästar generellt känsliga för bensylpenicillin. Penicillinresistens är däremot vanligt hos Staphylococcus pseudintermedius från hundar och förekommer hos S. aureus från hästar och S. felis från katter. Resistens hos E. coli från olika djurslag förekommer också och är vanligast hos isolat från träckprover från unga kalvar. Resistensundersökning är motiverat för val av lämpligt antibiotikum vid behandling, särskilt för stafylokocker, E. coli och Brachyspira spp.
Indikatorbakterier från friska djur
Resistens hos E. coli i tarmfloran hos friska djur kan använ-das som indikator för utbredningen av antibiotikaresistens hos bakteriefloran i en djurpopulation och indirekt som indi-kator på omfattningen av antibiotikaanvändning till djuren. I Sverige är förekomsten av resistens hos dessa indikatorbak-terier låg hos de flesta undersökta djurslag och situationen är gynnsam ur ett internationellt perspektiv.
SWEDRES |SVARM 201810
Summary
The situation in Sweden regarding antibiotic resistance in bacteria in humans and animals is still favourable from an international perspective. This confirms that our strategies to promote the rational use of antibiotics and to limit the spread of antibiotic resistance are effective. Despite our compara-tively good situation, there are problems with cross infection and increasing antibiotic resistance, which motivates contin-ued efforts in preventive work. An important example is the recurrent outbreaks of vancomycin-resistant enterococci (VRE) in hospitals. This is described in more detail in an In Focus section of this Swedres-Swarm report.
Over the last decades the consumption of antibiotics in Sweden has decreased in both humans and in animals. In addition, the sales of broad-spectrum antibiotics have decreased while the use of narrow-spectrum antibiotics has increased. Despite this, many of the monitored types of anti-biotic resistance have continued to increase over the years, even if exceptions to these negative trends occur.
Key findings 2018
• Two regions, Jämtland and Västerbotten, reached the national target for antibiotic prescriptions to humans of 250 prescriptions per 1 000 inhabitants per year. This long-term goal is intended to reduce unnecessary antibiotic use.
• The national average for antibiotic prescription to humans is now below 300 prescriptions per 1 000 inhabitants per years, which is a historically low level.
• One large and several small VRE outbreaks occurred in hospitals. VRE usually affects sensitive patient groups where the use of antibiotics is high. During the year, an outbreak strain of VRE caused septicaemia in five patients.
• High resistance to ciprofloxacin was seen in Escherichia coli and Klebsiella pneumoniae, both from urine and blood from humans. Ciprofloxacin is used in the treatment of febrile urinary tract infection, and when used for empirical treat-ment it is important to consider this high level of resis-tance.
• Resistance in E. coli to mecillinam and nitrofurantoin, used for first-line treatment of uncomplicated urinary tract infection, is still low, four and one percent respectively.
• High levels of resistance to erythromycin and clindamy-cin were observed in Streptococcus agalactiae (GBS). These antibiotics are alternatives to penicillin in cases of allergy. S. agalactiae can cause severe infections in children in the neonatal period.
• Increasing numbers of Enterobacteriaceae with ESBLCARBA were observed. These are extremely resistant, and there are few treatment options in case of infection. Early detec-tion and prevention of spread within human health care is therefore important.
• Consumption of antibiotics for animals is stable at a low level and is dominated by narrow-spectrum penicillin.
• MRSA is unusual among both farm and companion animals.
• The occurrence of ESBL-producing E. coli in caecal and meat samples from broilers has decreased significantly com pared to previous years.
• ESBLCARBA-producing bacteria have not been detected in animals in Sweden.
Consumption of antibiotics
Antibiotic consumption in humansThe total sales of antibiotics to humans in Sweden was 4.4% lower in 2018 than in 2017 and the national average is now 11.7 DDD per 1 000 inhabitants per day. This figure encompasses all antibiotics sold on prescription to individu-als, as well as antibiotics sold to hospitals and other health care facilities for dispensing to patients and clients. For the Region Dalarna, only prescription data are included because the region failed to supply data on hospital sales during 2018. The sales of antibiotics have decreased by approximately 19% since the year 2000.
Outpatient care
The decrease in sales in outpatient care during 2018 encom-passes the majority of all antibiotic groups, except beta-lactamase resistant penicillins (J01CF), trimethoprim with sulphonamides (J01EE), and nitrofurantoin (J01XE). Persistent availability problems affecting oral suspensions of amoxicillin with clavulanic acid and cefadroxil, as well as the withdrawal of ceftibuten in 2017, might partly explain the lower sales of combinations of penicillins (J01CR) and cephalosporins (J01DB-DE).
Hospitals and other health and social care facilities
In 2018, sales were slightly lower than in 2017 and the overall figure is now 1.52 DDD per 1 000 inhabitants per day. This reflects all antibiotics sold for dispensing in hospitals, nursing homes and other healthcare facilities.
Data from acute care hospitals show that the consumption of antibiotics was slightly higher in 2018 compared with 2017, both when measured as DDD per 100 patient-days and as DDD per 100 admissions. Beta-lactamase-resistant penicillins (J01CF) still represent the greatest number of DDDs. There are large differences in consumption of antibiotics between Swedish acute care hospitals, for example, in the relative use of narrow-spectrum penicillins, which make up between 6.1% and 18.6% of the total acute care hospital consump-tion measured in DDDs. The use of broad-spectrum antibi-otics – cephalosporins, carbapenems, fluoroquinolones, and piperacillin with tazobactam – also shows regional variation in terms of which substances are used, although the overall level is similar within the country.
Sales of antibiotics for animalsIn 2018, reported sales of antibiotics for animals were 10 042 kg, of which 58% were narrow-spectrum penicillins. The corresponding figures for 2009 were 15 368 kg and 50%, respectively.
SWEDRES |SVARM 2018 11
Since the withdrawal of growth-promoting antibiotics from the market in 1986, the total sales of antibiotics have decreased by around two thirds when corrected for population sizes over time. During the 1990s, sales of veterinary products for medication of groups of animals decreased, and in the past decade there has also been a decrease in sales of products for use in individual animals.
Comparing consumption of antibiotics in human and veterinary medicine In 2018, a total of 59.5 tonnes of antibiotics were sold for human use and 10.0 tonnes were sold for animal use. Measured as milligrams of active substance per kilogram biomass, the consumption was 88.6 and 12.7 milligrams per kilogram, respectively. Consumption by humans still domi-nates for all included classes of antibiotics except for trime-thoprim-sulphonamides.
Notifiable resistance
ESBL-producing EnterobacteriaceaeESBL-producing Enterobacteriaceae in humans have been subject to mandatory notification since 2007. This is the most common of the antibiotic resistance types where noti-fication is required.
Results 2018, Enterobacteriaceae with ESBL
• The number of reported cases: 10 341 (previous year 10 084), relative change +2.5%.
• The number of cases of septicaemia: 703 (previous year 594), relative change +18%.
• As in previous years, E. coli was the most common species, 87%, followed by K. pneumoniae, 9%.
Results 2018, Enterobacteriaceae with ESBLCARBA• The number of reported cases: 144 (previous year 116), rela-
tive change +24%.• The number of cases with septicaemia: 7 (previous year 2).• Among Enterobacteriaceae with ESBLCARBA, E. coli was the
most common species, 60%, followed by K. pneumoniae, 33%.
ESBL-producing Enterobacteriaceae are, with the exception of broilers, rare among animals in Sweden. In 2018, the occur-rence of ESBL-producing E. coli in caecal and meat samples from broilers, caecal samples from turkeys, and intestinal samples from cattle under one year of age were investigated with screening methods. Such bacteria were isolated from 13% of the intestinal samples and 12% of the meat samples from broilers of Swedish origin. This is a significant decrease from previous years and is most likely explained by decreased occurrence of ESBL-producing E. coli in the breeding pyra-mid. Bacteria that form ESBLCARBA have not been detected in animals in Sweden.
MRSACommunity-acquired infection has long been the most common type in humans, with more than two-thirds of the cases. In 2015, it was divided into family-/household-related infection and community-acquired infection. Family/house-hold-related infections accounted for 39% of the cases in 2018.
Results 2018
• The number of reported human cases: 3 864 (previous year 3 735), relative change + 3.5%.
• The number of cases with septicaemia: 64 (previous year 55), relative change + 16%.
• About 30 smaller outbreaks in health- and elderly care were reported.
The occurrence of MRSA in animals in Sweden is still low, which limits the spread from animals to humans. MRSA was found sporadically in cats, dogs and horses in 2018, and MRSA with mecC was detected in samples from hedgehogs in a research project. In companion animals, the same types of MRSA as in humans dominate, indicating a human source of MRSA in these animals. In horses, livestock-associated MRSA clonal complex 398 is the most common.
MRSPIn 2018, there were 57 cases of methicillin-resistant Staphylococcus pseudintermedius (MRSP) notified to the Swedish Board of Agriculture. All cases except one were related to dogs. This number is about the same level as in recent years. The epide-miology of MRSP is becoming more diverse compared to earlier years with several sequence types occurring.
MRSP in humans is not notifiable.
PNSP
Results 2018
• The number of reported cases: 91 (previous year 61), rela-tive change + 50%.
• The number of cases with septicaemia: 3 (previous year 5).• An outbreak in preschools in Örebro county that included
18 cases.
VRE
Results 2018
• The number of reported cases: 444 (previous year 244), relative change + 82%.
• The number of reported cases of E. faecium with vanco-mycin resistance: 438 (previous year 236), relative change +54%.
• The number of reported cases: of E. faecalis with vancomy-cin resistance: 6 (previous year 8).
• The number of cases with septicaemia: 9 (previous year 2).•Nineteen hospital-related outbreaks were reported during
the year, including one larger (261 cases), three smaller with 5-15 cases each, and the rest with only 2-4 cases each.
SWEDRES |SVARM 201812
Zoonotic pathogens
Salmonella is rare in animals in Sweden, and few incidents involve antibiotic-resistant strains. Strains with ESBL resis-tance have never been found in isolates from animals in Sweden, and resistance to fluoroquinolones is rare. Isolates from human invasive infections are markedly more resistant, which makes animals in Sweden an unlikely source for these infections.
Campylobacter from animals in Sweden are generally suscep-tible to relevant antibiotics, and resistance to erythromycin, for example, is most uncommon.
Infections, either in humans or in animals, caused by Salmonella and Campylobacter are usually not treated with antibiotics. In humans, only a small proportion are tested for susceptibility, and most of these isolates are related to serious infections. See the “Comparative analysis” section of each bacterium.
Human clinical isolates
All data for these compilations are collected automatically via Svebar, a collaboration between the clinical laboratories and the Public Health Agency.•E. coli: Resistance in blood isolates to cefotaxime and
ceftazidime was 7-8%, to compare with the 470 reported cases of E. coli ESBL from blood in 2018. Resistance to ciprofloxacin is now 18 and 12%, in isolates from blood and urine, respectively and this needs to be noted when choos-ing empirical treatment for febrile urinary tract infection. Resistance in E. coli to mecillinam and nitrofurantoin, used for first-line treatment of uncomplicated urinary tract infec-tion, is still low, four and one percent respectively.
•K. pneumoniae: Resistance of blood isolates to cefotaxime and ceftazidime was 5%, to compare with the 66 reported cases of K. pneumoniae ESBL from blood 2018: 66. As for E. coli, resistance to ciprofloxacin is now relatively high, 10-11% in isolates from blood and urine.
•S. aureus: Resistance to cefoxitin (which is indicative of MRSA) in isolates from blood and samples from skin and soft tissue was 1.9%, to compare with the 64 of reported cases of MRSA from blood 2018.
• S. agalactiae (GBS): Resistance to erythromycin and clin-damycin has gradually increased and is now about 20% for both of these antibiotics in blood isolates.
•Clostridioides difficile: The incidence has decreased by 25% from 2009 to 2016 and subsequently remained unchanged. Like previous years, all isolates tested were susceptible to metronidazole and vancomycin.
Animal clinical isolates
Bacteria causing clinical disease in animals are mostly suscep-tible to antibiotics relevant for treatment. Respiratory patho-gens from farm animals and horses are generally susceptible to bensylpenicillin, but penicillin resistance is common in Staphylococcus pseudintermedius from dogs and occurs in S. aureus from horses and S. felis from cats. Resistance in E. coli occurs in all animals but is most prominent in enteric isolates from young calves. Susceptibility testing for guidance in antibiotic therapy is warranted, especially for staphylococci, E. coli and, Brachyspira spp.
Indicator bacteria from healthy animals
Antibiotic resistance in E. coli from the intestinal flora of healthy animals serves as an indicator for the presence of resis-tance in an animal population. The prevalence of acquired resistance in such commensal bacteria also indirectly indicates the magnitude of the selective pressure from the use of anti-biotics in an animal population. The prevalence of resistance in indicator bacteria from animals in Sweden is generally low, and the situation is favourable in an international perspective.
SWEDRES |SVARM 2018 13
Guidance for readers
The Swedres-Svarm report is the result of a cooperation between the Public Health Agency of Sweden and the National Veterinary Institute with the aim to present data relating to both humans and animals on the use of antibiotics and on antibiotic resistance in a joint report.
Data on occurrence of notifiable diseases caused by resis-tant bacteria as well as data on resistance in zoonotic bacte-ria and in bacteria from clinical submissions are presented. Additionally, the report includes data on sales of antibiotics and resistance in so called indicator bacteria from healthy animals and from food of animal origin.
Data on resistance in bacteria from humans are obtained from several sources and national programs and compiled by the Public Health Agency of Sweden in Swedres. In contrast, data on animals and food, compiled by the National Veterinary Institute, are from the national monitoring program in the veterinary field Svarm. This program is specifically designed to monitor resistance in bacteria from animals and food and is organised and run at the National Veterinary Institute. Data in the veterinary field also emanate from other sources, such as the SvarmPat project and specific research projects. For details on data sources see Background data, material, methods and references.
FIGURE 1.1. Schematic view of antimicrobial consumption and resistance monitored in Sweden 2018. Resistance in bacteria from humans and consumption for humans to the left and resistance in bacteria from animals and food and consumption for animals to the right.
Antibiotic Resistance
Mandatory reporting Voluntary reporting
Sampling
Laboratories
Data compilation
Mandatory reporting Voluntary reporting
Svarm SvarmPat
SWEDRES-SVARM
Antibiotic Consumption
• Sales in outpatient care and hospital care, data from the eHealth Agency and regions
• Total sales for animals based on data from the eHealth Agency • Analysed by SVA and SBA
Clinical microbiological laboratories
Health care visits
Clinical submission• ESBL/pAmpC/ CPE• MRSA• M. tuberculosis• N. gonorrhoeae• N. meningitidis• PNSP• VRE
Clinical submissionHuman pathogens causing• Blood-stream infections (e.g. E. coli, S. aureus)• Urinary tract infections (e.g. E. coli, K. pneumoniae)• Wound infections (e.g. S. aureus)• Respiratory tract infections (e.g. H. influenzae, S. pneumoniae)• C. difficile infection
Screening/ Case finding• ESBL/pAmpC/ CPE• MRSA• M. tuberculosis• N. gonorrhoeae• N. meningitidis• PNSP• VRE
SVA
Veterinary health care visitsSlaughterhouseRetail stores
Diseased animals• Animal pathogens
Diseased animals• Salmonella• MRSA/MRSP• ESBL/pAmpC/CPE
• Animal pathogens
Fresh meat• ESBL/pAmpC/CPE
Healthy animals • E. coli • ESBL/pAmpC/CPE
• Campylobacter
• Salmonella
Submission of isolatesMicrobiological characterization • C. difficile• ESBL/pAmpC/ CPE• MRSA• PNSP• VRE• M. tuberculosis• M. gonorrhoeae• N. meningitidis• CoRE
PHAS SVA
SWEDRES |SVARM 201814
Embedded files in the PDF-file version of the reportThe data from many of the tables and figures in Swedres-Svarm can be accessed from embedded Excel-files. To access the embedded files, indicated with paperclips, we recom-mend using Adobe Acrobat Reader.
Antibiotic consumptionAntibacterials for systemic use in human are indexed as J01 in the Anatomical Therapeutic Chemical classification system. Unfortunately, the J01 group also includes the antiseptic substance methenamine. This is not an antibiotic and has no influence on antibiotic resistance. Throughout this report, methenamine is consequently excluded whenever antibiotics are referred to or presented as a group.
Comparison of consumption of antibiotics between regions and to elderly people over time is complicated by the fact that there are differences in how medicines are distributed to residents in nursing homes. In Sweden, most people living in nursing homes still get their medicines by prescription, whereby data is included in outpatient sales. However, there are also nursing homes where medicines are bought by the facility and then dispensed to the residents. Such consump-tion is included in hospital care data. Since routines differ between regions and over time, the appraisal of antibiotic use to elderly people is not entirely reliable.
Wherever sales of antibiotics to a certain group of people is displayed (children 0-6 years, women 18-79 years, inhabit-ants in a region), the denominator is the number of individu-als in the same group.
In this report the term ‘outpatient care’ includes all anti-biotic sales on prescriptions to individuals. ‘Hospital care’ includes sales of antibiotics to hospitals, nursing homes and other health and social care facilities). Since national data on antibiotic consumption in hospitals in Sweden is thus combined with sales to some nursing homes and other facili-ties, the figure is not suitable for evaluation of antibiotic use in hospital care. Therefore, data on sales exclusively to acute care hospitals have been provided by pharmacists in local Strama groups in all regions.
National treatment recommendations may be adapted with local variations by the regional drug and therapeutics committees, and therefore the prescribed daily doses for certain indications can vary between regions. This should be kept in mind, as it may affect comparisons.
Antibiotic resistance
Swedres - Humans
Most of the data on resistance in Swedres is derived from routine diagnostic samples sent for testing at clinical laborato-ries. The results are mostly presented as proportion resistance in tables or graphs. The methods used for antibiotic suscep-tibility testing, whether MIC determination or disk diffusion inhibition zones, are standardised by European Committee on Antimicrobial Susceptibility Testing (EUCAST) and avail-able online at www.eucast.org. The methods and breakpoints routinely used in Sweden are available at www.nordicast.org. EUCAST also presents yearly updated interpretative criteria for clinical use in human medicine, i.e. clinical breakpoints, also available at www.eucast.org. In Swedres, only MIC results for Clostridioides difficile were interpreted using ECOFFs.
Svarm - Animals and food
The vast majority of data on resistance in Svarm are from MIC determinations performed at the National Veterinary Institute using broth microdilution following the standards of the Clinical and Laboratory Standards Institute (CLSI, 2018a). Results for isolates of zoonotic and indicator bacteria are interpreted according to ECOFFs from EUCAST (www.eucast.org). Clinical isolates from animals are classified by ECOFFs when such values are available. Interpretive criteria used are given in the section Materials and methods resis-tance in bacteria from animals.
ECOFFs classify isolates with acquired reduced suscepti-bility as non-wild type. In Svarm, non-wild type isolates are called “resistant”. This classification is relevant for monitor-ing purposes, but it should be understood that resistance defined in this manner not always implies clinical resistance.
Since the first report from Svarm, some interpretive crite-ria (ECOFFs) have been changed by EUCAST. To facilitate comparisons when retrospect data are presented, levels of resistance have been recalculated using current interpretive criteria if not otherwise stated.
http://www.eucast.orghttp://www.nordicast.org
SWEDRES |SVARM 2018 15
Indicator bacteria in animals
In Svarm, Escherichia coli, Enterococcus faecalis and E. faecium serve as indicators for presence of antibiotic resistance in the enteric flora of healthy animals and in the flora contami-nating food. The prevalence of acquired resistance in such commensal bacteria in animals indicates the magnitude of the selective pressure from use of antibiotics in an animal population. Most bacteria of the enteric flora are unlikely to cause disease, but they can be reservoirs for resistance genes that can spread to bacteria that cause infections in animals or humans. Prevalence of resistance in indicator bacteria contam-inating meat indicates the magnitude of the potential human exposure to such reservoirs in food producing animals.
Presentation of MIC distributions in bacteria from animals
Results from MIC determinations in Svarm are presented as distributions of MICs in tables of a uniform design as below. Distributions are given as percentages of isolates tested. In the tables, white fields denote range of dilutions tested for each antibiotic and vertical bold lines indicate cut-off values used to define resistance.
The percentage of isolates with a certain MIC of an anti-biotic is given in the corresponding white field. For MICs above the range tested of an antibiotic (>X mg/L) the percent-age is given in the field closest to the range, i.e. in the first shaded field to the right of the tested range. For MICs equal to or lower than the lowest concentration tested for an anti-biotic (≤Y mg/L) the percentage is given as the lowest tested concentration, i.e. in the first white field of the tested range.
Multidrug resistanceThe terms multidrug resistance (MDR), multiresistance and multiresistant are in Svarm used for isolates with phenotypi-cally identified acquired resistance to three or more antibiotic classes. This implies, for example, that resistance to cipro-floxacin, enrofloxacin and nalidixic acid represents resistance to one class of antibiotics.
Example of a table with MIC distributions�
Antibiotic Resistance(%)Distribution (%) of MICs (mg/L)
≤ 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 >64
Ciprofloxacin 21 21.0 52.0 6.0 1.0 20.0
Erythromycin 0 93.0 4.0 3.0
Tetracycline 2 75.0 22.0 1.0 1.0 1.0
Abbreviations of generic antibiotic namesWhen abbreviations for antibiotics were needed in tables or graphs the following were used.
Amp Ampicillin
Azt
Bac
Azithromycin
Bacitracin
Caz Ceftazidime
Cdr Cefadroxil
Cer Ceftiofur
Cet Cephalothin
Chl Chloramphenicol
Cip Ciprofloxacin
Cli Clindamycin
Col Colistin
Ctx Cefotaxime
Enr Enrofloxacin
Ery Erythromycin
Flf Florfenicol
Fox Cefoxitin
Fus Fusidic acid
Gen Gentamicin
Imp Imipenem
Kan Kanamycin
Lin Linezolid
Mec Mecillinam
Mer Meropenem
Nal Nalidixic acid
Nar Narasin
Pen Penicillin G
Ptz Piperacillin-Tazobactam
Rif Rifampicin
Str Streptomycin
Sul Sulphonamide
Tet Tetracycline
Tgc Tigecycline
Tmp Trimethoprim
Tsu Trimethoprim-sulfonamide
Tob Tobramycin
Van Vancomycin
Oxa Oxacillin
SWEDRES |SVARM 201816
AST Antimicrobial Susceptibility Testing
ATC Anatomical therapeutic chemical classification system
CDI Clostridioides difficile infection
CMO County medical officer
DDD Defined daily dose
ECDC European Centre for Disease Prevention and Control
ECOFF Epidemiological cut-off value for non-susceptibility
EARSS/EARS-Net European antimicrobial resistance surveillance system/network
ESC Extended spectrum cephalosporin
ESBL Extended spectrum beta-lactamase
ESBLA Extended spectrum beta-lactamase, plasmid-mediated, inhibited by clavulanic acid (A = classical)
ESBLM Extended spectrum beta-lactamase inhibited by cloxacillin, also called plasmid-mediated AmpC
(M = miscellaneous)
ESBLCARBA Extended spectrum beta-lactamase with activity against carbapenems
EUCAST European Committee on Antimicrobial Susceptibility Testing
GAS Group A streptococci or Streptococcus pyogenes
GBS Group B streptococci or Streptococcus agalactiae
HLAR High-level aminoglycoside resistance (e.g. in Enterococcus)
MALDI-TOF MS Matrix-assisted-laser-desorption/ionization time-of-flight mass spectrometry
MDR Multidrug resistance, i.e. phenotypic resistance to three or more antibiotic classes
MIC Minimal inhibitory concentration
MLST Multilocus sequence typing
MRB Multi-resistant bacteria
MRSA Methicillin-resistant Staphylococcus aureus
MRSP Methicillin-resistant Staphylococcus pseudintermedius
NordicAST Nordic Committee on Antimicrobial Susceptibility Testing
PNSP Penicillin non-susceptible pneumococci
PVL Panton-Valentine leukocidin
ResNet Webb application for resistance surveillance and quality control programme
RTI Respiratory tract infection
spa Staphylococcus aureus protein A gene
SSTI Skin and soft tissue infection
ST Sequence type
Strama Swedish strategic programme against antibiotic resistance
Svarm Swedish veterinary antibiotic resistance monitoring programme
Swedres Swedish utilisation and resistance in human medicine
TB Tuberculosis
UTI Urinary tract infection
VRE Vancomycin resistant enterococci
XDR Extreme drug resistance (used for Mycobacterium tuberculosis)
Abbreviations
SWEDRES |SVARM 2018 17
In 2018, the total sales of antibiotics (J01 excl. methenamine) in Sweden (outpatient care and hospital care) was 4.4% lower than in 2017 (12.3 and 11.7 DDD per 1 000 inhabit-ants per day, respectively). This adds to an overall downward trend, with approximately 19% less sales compared to the year 2000. A comparison with EU/EEA countries (European Centre for Disease Prevention and Control, 2018), where figures range from 34.1 to 11.0 DDD per 1 000 inhabitants
FIGURE 1�2� Sales of antibiotics to humans, all genders, ATC-5, 2014-2018, DDD/1 000 inhabitants per day. Data includes prescriptions to individuals as well as antibiotics dispensed in hospitals, nursing homes etc.
DD
D/1
000
inha
bita
nts
per
day
0
1
2
3
4
2014 2015 2016 2017 2018
J0
1AA
- Tet
racy
cline
s
J01C
A - P
enici
llins w
ith
ext
ende
d sp
ectru
m
J01C
E - B
eta-l
acta
mas
e
sens
itive
penic
illins
J01C
F - B
eta-l
acta
mas
e-
resis
tant
pen
icillin
s
J01C
R - C
ombin
ation
s
of p
enici
llins
J01D
B - J
01DE
-
Ceph
alosp
orins
J01D
H - C
arba
pene
ms
J01E
A - T
rimet
hopr
im
J01E
E - T
rimet
hopr
im
with
sulph
onam
ides
J0
1FA
- Mac
rolid
es
J01F
F - L
incos
amide
s
J01G
B -
Amino
glyco
sides
J0
1MA
- Fluo
roqu
inolon
es
J0
1XE
- Nitr
ofur
anto
in
J01X
X - O
ther
antib
acte
rials
FIGURE 1�1� Sales of antibiotics (J01 excl. methenamine) to humans, all genders, per region, 2003-2018 in three-year intervals, DDD/1 000 inhabitants per day. Data includes prescriptions to individuals as well as antibiotics dispensed in hospitals, nursing homes etc.
0
2
4
6
8
10
12
16
18
DD
D/1
000
inha
bita
nts
per d
ay
2003 2006 2009 2012 2015 2018
Got
land
Sto
ckho
lm
Upp
sala
Skå
ne
Kro
nobe
rg
Öre
bro
Swed
en
Väs
tman
land
Vär
mlan
d
Blek
inge
Söd
erm
anlan
d
Väs
tra G
ötala
nd
Nor
rbot
ten
Kalm
ar
Hall
and
Öst
ergö
tland
Väs
tern
orrla
nd
Gäv
lebor
g
Väs
terb
otte
n
Jönk
öping
Jäm
tland
14
per day with a population-weighted mean of 23.4, gives an indication of Sweden’s restrictive position regarding antibi-otic prescribing. However, there are considerable differences within Sweden with total sales ranging from 13.6 DDD per 1 000 inhabitants per day in Region Gotland to 9.7 in Region Jämtland, Figure 1.1. Region Dalarna is not included in the statistics showing total sales, due to failure to report data for sales of antibiotics to hospitals and other care facilities.
Consumption of antibiotics in humans
Total consumption of antibiotics in humans
Blad1
Sales of antibiotics (J01 excl. methenamine) to humans, all genders, per county, 2003-2018 in three-year intervals, DDD/1000 inhabitants and day. Data includes prescriptions to individuals as well as antibiotics dispensed in hospitals, nursing homes etc.
200320062009201220152018
Gotland14.3213.6012.6413.0712.5413.56
Stockholm15.6116.5915.6215.5214.0512.83
Uppsala14.8215.3414.7114.9913.8412.60
Skåne15.9716.4015.3314.8913.3512.37
Kronoberg14.1014.5414.1213.6612.1112.07
Västmanland12.7513.9213.6013.7112.6111.91
Örebro13.6713.8813.4714.2612.9611.82
Sweden14.3815.0214.3714.2212.7111.73
Värmland11.6312.6712.5013.0612.5011.61
Norrbotten12.1712.9912.7712.8811.9111.45
Västra Götaland14.5115.2114.5614.6712.3111.31
Södermanland13.0513.3512.9212.8211.9411.21
Kalmar13.9614.4913.4913.2212.1111.11
Östergötland12.1512.6612.7112.7111.7911.00
Västernorrland12.4613.1112.5812.1111.3510.93
Halland13.5714.5913.4113.4111.5510.75
Gävleborg12.2012.8912.4712.3611.3610.73
Jönköping11.7112.5011.9912.4610.9210.45
Västerbotten11.5212.1612.1212.0410.8110.34
Blekinge14.5215.3914.4613.4312.2710.08
Jämtland11.6211.7411.5911.5210.439.68
2003 Gotland Stockholm Uppsala Skåne Kronoberg Västmanland ÖrebroSweden Värmland Norrbotten Västra Götaland Södermanland Kalmar Östergötland Västernorrland Halland Gävleborg Jönköping Västerbotten Blekinge Jämtland14.31535861529268815.61483758487296914.82249552958778715.96610151154715914.0989259198535112.75092809409618913.67294132722376314.38161733183568111.62587355381651812.16959602023986714.51177780013568113.04952272974266113.9606817827725512.14642823184566612.45773921769804613.56511544813883312.19546112729600511.71437139899982111.51856037923355614.51755018031007611.6165510162330752006 Gotland Stockholm Uppsala Skåne Kronoberg Västmanland ÖrebroSweden Värmland Norrbotten Västra Götaland Södermanland Kalmar Östergötland Västernorrland Halland Gävleborg Jönköping Västerbotten Blekinge Jämtland13.59718494461262316.58537506743853715.33836962541301816.39762399655002114.53668874861925513.92206136868490413.88371909714103215.01612390238625112.67130086119194512.99240991237969715.20688515934189613.35260825482971514.49480592766844612.65704350391651913.10944604415916414.58857059087143112.8931817424162812.50423291616789212.15840356563562915.39416761037916411.7429201791127072009 Gotland Stockholm Uppsala Skåne Kronoberg Västmanland ÖrebroSweden Värmland Norrbotten Västra Götaland Södermanland Kalmar Östergötland Västernorrland Halland Gävleborg Jönköping Västerbotten Blekinge Jämtland12.64167905866736215.62020667509452614.71478908388474215.32523687428176614.11867436675859713.59901503838591613.46664863573023814.37213390466762812.49638014598095412.76984156279502314.56230022147552612.9235588797768513.49219857562935112.71231693208358312.57710111292505513.41471818103850212.4659147251982611.99198680900772412.12471017532368314.45815466020542811.585142878082232012 Gotland Stockholm Uppsala Skåne Kronoberg Västmanland ÖrebroSweden Värmland Norrbotten Västra Götaland Södermanland Kalmar Östergötland Västernorrland Halland Gävleborg Jönköping Västerbotten Blekinge Jämtland13.07255426625793715.51833334165491814.98753158620988314.89383380997669813.66488267734054313.7131154525870114.26099724544145414.2193469924169413.06016479877015312.88289835917168514.67455938758212512.81690515667415813.22150945705204712.71381141757374812.10911289149691713.40615673586680912.35566061879066712.45818450977447312.04094565336633613.43157193224527811.5195451707386932015 Gotland Stockholm Uppsala Skåne Kronoberg Västmanland ÖrebroSweden Värmland Norrbotten Västra Götaland Södermanland Kalmar Östergötland Västernorrland Halland Gävleborg Jönköping Västerbotten Blekinge Jämtland12.54392808907040514.05362663166552113.8440554145788513.34598167861624612.11229143645849112.61295165768536112.96413798942237412.71280075785757212.49812180657489511.90951836527828112.30867964590408911.94308025395368312.10759330352247311.78843533884360411.3512275297598511.55481215395431211.36284497989979210.91565270095736710.80910806286368112.27061683512299910.4309475682810822018 Gotland Stockholm Uppsala Skåne Kronoberg Västmanland ÖrebroSweden Värmland Norrbotten Västra Götaland Södermanland Kalmar Östergötland Västernorrland Halland Gävleborg Jönköping Västerbotten Blekinge Jämtland13.56139088028222712.82934680093507412.60120389607781112.37236065981626112.06677165858917911.90790061715715511.81634525898947911.7311.61422052831075511.44597363738028811.30660460412554811.21477648961276711.10932247759719110.99840470137503710.93429026072218610.75301559160305610.72566403732756910.44916377029316510.33680820106393510.0768975088109679.6822416761451588
DDD/1 000 inhabitants and day
helenerikssonFile AttachmentFig 1.1 Total consumption per region_2003-2018.xlsx
Blad1
Sales of antibiotics to humans, all genders, ATC5, 2014-2018, DDD/1 000 inhabitants and day. Data includes prescriptions to individuals as well as antibiotics dispensed in hospitals, nursing homes etc.
200020052012201320142015201620172018
J01AA - Tetracyclines3.053.523.393.062.852.752.582.532.32
J01CA- Penicillins with extended spectrum1.371.551.601.561.551.561.541.531.51
J01CE - Betalactamase sensitive penicillins4.844.124.133.733.423.423.443.393.13
J01CF - Betalactamase-resistant penicillins1.241.381.821.881.881.851.841.801.81
J01CR - Combinations of penicillins0.220.250.320.330.350.380.400.430.43
J01DB - J01DE - Cephalosporins0.770.640.320.290.270.270.270.210.20
J01DH - Carbapenems0.030.040.050.050.050.060.050.060.06
J01EA - Trimethoprim0.620.550.220.190.170.150.130.110.11
J01EE - Trimethoprim with sulphonamides0.190.210.290.300.300.310.310.310.33
J01FA - Macrolides0.530.440.330.300.270.270.270.270.24
J01FF - Lincosamides0.240.320.370.360.360.360.360.350.33
J01GB - Aminoglycosides0.020.020.030.030.030.030.030.030.02
J01MA - Fluoroquinolones1.161.190.920.880.860.850.820.780.75
J01XE - Nitrofurantoin0.140.240.370.390.410.410.410.420.43
J01XX - Other antibacterials1.561.881.281.251.231.211.171.121.11
2014 J01AA - TetracyclinesJ01CA- Penicillins with extended spectrum J01CE - Betalactamase sensitive penicillins J01CF - Betalactamase-resistant penicillins J01CR - Combinations of penicillinsJ01DB - J01DE - Cephalosporins J01DH - carbapenems J01EA - Trimethoprim J01EE - Trimethoprim with sulphonamides J01FA - Macrolides J01FF - Lincosamides J01GB - Aminoglycosides J01MA - Fluoroquinolones J01XE - Nitrofurantoin J01XX - Other antibacterials2.85429692076926771.55121464092965193.42081303085816351.8809093101935590.354710512143227960.270335533907384245.3454811136957853E-20.166075983442856540.298215074428881340.272293915271580530.358509484909018292.7531161620219943E-20.857123279148562230.40664136735691731.22710821382410762015 J01AA - TetracyclinesJ01CA- Penicillins with extended spectrum J01CE - Betalactamase sensitive penicillins J01CF - Betalactamase-resistant penicillins J01CR - Combinations of penicillinsJ01DB - J01DE - Cephalosporins J01DH - carbapenems J01EA - Trimethoprim J01EE - Trimethoprim with sulphonamides J01FA - Macrolides J01FF - Lincosamides J01GB - Aminoglycosides J01MA - Fluoroquinolones J01XE - Nitrofurantoin J01XX - Other antibacterials2.74595831873828411.55727693827555363.42027199159465711.8548514393961020.378661611000716660.273802923551097815.6259331974870909E-20.152763718134901390.307000951568294430.265128964420224930.357731193716246792.762126560009609E-20.845494176554801520.40948730713972471.21358468984873842016 J01AA - TetracyclinesJ01CA- Penicillins with extended spectrum J01CE - Betalactamase sensitive penicillins J01CF - Betalactamase-resistant penicillins J01CR - Combinations of penicillinsJ01DB - J01DE - Cephalosporins J01DH - carbapenems J01EA - Trimethoprim J01EE - Trimethoprim with sulphonamides J01FA - Macrolides J01FF - Lincosamides J01GB - Aminoglycosides J01MA - Fluoroquinolones J01XE - Nitrofurantoin J01XX - Other antibacterials2.57973806960590621.53697372737656313.43850837776722031.84070046345235690.404699244275581130.268849868287794065.4239150368913865E-20.126473245922569670.310029257243851830.268583087144916130.356387958492500552.7534135311110989E-20.819362262333912960.413103376835834651.16663400548035062017 J01AA - TetracyclinesJ01CA- Penicillins with extended spectrum J01CE - Betalactamase sensitive penicillins J01CF - Betalactamase-resistant penicillins J01CR - Combinations of penicillinsJ01DB - J01DE - Cephalosporins J01DH - carbapenems J01EA - Trimethoprim J01EE - Trimethoprim with sulphonamides J01FA - Macrolides J01FF - Lincosamides J01GB - Aminoglycosides J01MA - Fluoroquinolones J01XE - Nitrofurantoin J01XX - Other antibacterials2.53020796718118611.52697909511054293.38782925288227951.79670106653411250.425009158520587850.211612912232421265.5316514958906625E-20.114101116099378560.312625742301461620.265107487732477170.352919252737906422.7024727180336116E-20.775133995521915420.424098822522839811.12455975091340672018 J01AA - TetracyclinesJ01CA- Penicillins with extended spectrum J01CE - Betalactamase sensitive penicillins J01CF - Betalactamase-resistant penicillins J01CR - Combinations of penicillinsJ01DB - J01DE - Cephalosporins J01DH - carbapenems J01EA - Trimethoprim J01EE - Trimethoprim with sulphonamides J01FA - Macrolides J01FF - Lincosamides J01GB - Aminoglycosides J01MA - Fluoroquinolones J01XE - Nitrofurantoin J01XX - Other antibacterials2.32349189613969731.50810018666698363.13402296081321771.80643935708798290.433575588897133820.199534014730759355.6032805138968564E-20.107607679087581040.329452264465179450.23919426118655840.334589342104989972.3544352380029852E-20.747132010295503470.426304238060168981.10642881832867972000 J01AA - TetracyclinesJ01CA- Penicillins with extended spectrum J01CE - Betalactamase sensitive penicillins J01CF - Betalactamase-resistant penicillins J01CR - Combinations of penicillinsJ01DB - J01DE - Cephalosporins J01DH - carbapenems J01EA - Trimethoprim J01EE - Trimethoprim with sulphonamides J01FA - Macrolides J01FF - Lincosamides J01GB - Aminoglycosides J01MA - Fluoroquinolones J01XE - Nitrofurantoin J01XX - Other antibacterials3.04952343974405251.37082435650253114.84176384348791091.24327132057736310.219895582305587030.766439528407002693.2082706559265387E-20.616751867261050910.190428933161849720.527388006750135310.239111276238189311.6614386937555389E-21.16266920302496460.139856822214032921.55814451912758112005 J01AA - TetracyclinesJ01CA- Penicillins with extended spectrum J01CE - Betalactamase sensitive penicillins J01CF - Betalactamase-resistant penicillins J01CR - Combinations of penicillinsJ01DB - J01DE - Cephalosporins J01DH - carbapenems J01EA - Trimethoprim J01EE - Trimethoprim with sulphonamides J01FA - Macrolides J01FF - Lincosamides J01GB - Aminoglycosides J01MA - Fluoroquinolones J01XE - Nitrofurantoin J01XX - Other antibacterials3.52191430245334971.5510517189514334.12136595070006531.37954244358118520.248181535104874010.641180988034178114.2728183499164622E-20.554685325410385840.214931138029097080.444865518595567110.324318177026626852.1906496053847313E-21.18640242434501660.244708288893186961.88220915045165582012 J01AA - TetracyclinesJ01CA- Penicillins with extended spectrum J01CE - Betalactamase sensitive penicillins J01CF - Betalactamase-resistant penicillins J01CR - Combinations of penicillinsJ01DB - J01DE - Cephalosporins J01DH - carbapenems J01EA - Trimethoprim J01EE - Trimethoprim with sulphonamides J01FA - Macrolides J01FF - Lincosamides J01GB - Aminoglycosides J01MA - Fluoroquinolones J01XE - Nitrofurantoin J01XX - Other antibacterials3.39427714313274451.60432787164149954.1310009370290271.82012683298413940.321103668967508750.316056337832569095.366883108192616E-20.218792317258342890.288565795388457950.332194231249550660.366635909979763142.9468102964875412E-20.916723901826181240.371098337084581341.27621319733915062013 J01AA - TetracyclinesJ01CA- Penicillins with extended spectrum J01CE - Betalactamase sensitive penicillins J01CF - Betalactamase-resistant penicillins J01CR - Combinations of penicillinsJ01DB - J01DE - Cephalosporins J01DH - carbapenems J01EA - Trimethoprim J01EE - Trimethoprim with sulphonamides J01FA - Macrolides J01FF - Lincosamides J01GB - Aminoglycosides J01MA - Fluoroquinolones J01XE - Nitrofurantoin J01XX - Other antibacterials3.06182395039317791.56399639669239273.72556099840731171.88173433348463460.32958336570621860.292836232767499095.3707373848599936E-20.189255403295290590.295084641516389190.299244490155668840.364633352854577762.9023543522678798E-20.878535614490336350.391698408740217271.2499356428827715
DDD/1 000 inhabitants and day
helenerikssonFile AttachmentFig 1.2 Total consumption ATC_2014-2018.xlsx
SWEDRES |SVARM 201818
Approximately 85% (measured as DDD) of antibiotics in Sweden 2018 were sold on prescriptions in outpatient care. Beta-lactamase sensitive penicillins and tetracyclines were the two most sold antibiotic groups in Sweden during 2018, despite decreased sales. Overall, the sales of tetracyclines and fluoroquinolones continues the decrease seen in recent years. Nitrofurantoin, a recommended first-line treatment for uri-nary tract infections, continues to increase, Figure 1.2.
Antibiotics in outpatient careThe statistics for outpatient care reported in Swedres-Svarm includes all sales of antibiotics on prescriptions issued to indi-viduals; from healthcare centres in the community and from hospitals. Since 1992, the total sales of antibiotics on pre-scriptions has decreased by 47.2%, Figure 1.3. The greatest
FIGURE 1�3. Sales of antibiotics (J01 excl. methenamine) in outpatient care, to humans, all genders, per age, 1987-2018, prescriptions/ 1 000 inhabitants per year.
0
200
400
600
800
1000
1200
1400
1987
19
88
1989
19
90
1991
19
92
1993
19
94
1995
19
96
1997
19
98
1999
20
00
2001
20
02
2003
20
04
2005
20
06
2007
20
08
2009
20
10
2011
20
12
2013
20
14
Pre
scrip
tions
/100
0 in
habi
tant
s pe
r ye
ar
0 - 4 years 5 - 14 years 15 - 64 years
65 years and older All age groups
2015
20
16
2017
20
18
change during these years is seen among young children (the age group 0-4 years), where sales decreased by 75.9%, from 1 328 prescriptions per 1 000 inhabitants per year in 1992 to 320 in 2018. A multitude of structural factors may have contributed to this marked change, for example altered sup-ply chains for medicines, extension of the vaccination pro-gramme for children, organizational changes in the health care system, or demographic changes. Long-term strate-gic work targeting the quality of prescribing are described by Mölstad and colleagues in Lessons learnt during 20 years of the Swedish strategic programme against antibiotic resistance (Mölstad S, Löfmark S, et al. 2017).
The sales of antibiotics in outpatient care was 4.2% lower in 2018 than in 2017; 309 versus 296 prescriptions per 1 000 inhabitants per year, respectively. A statistically significant decrease is seen across all age groups (data not shown), and the rate of change appears higher over time. Less seasonal variation in sales of antibiotics is seen over the years (data available at https://www.folkhalsomyndigheten.se/folkhalso-rapportering-statistik/statistikdatabaser-och-visualisering/antibiotikastatistik/sverige/), which could indicate increased adherence to prescribing guidelines (Coenen S, Ferech M, et al. 2007).
The decrease in sales in outpatient care during 2018 encom-passes a majority of all antibiotic groups, except beta-lacta-mase resistant penicillins (J01CF), trimethoprim with sul-phonamides (J01EE), and nitrofurantoin (J01XE), Figure 1.4. Persistent availability problems affecting oral suspensions of amoxicillin with clavulanic acid and cefadroxil, as well as the withdrawal of ceftibuten in 2017, may partly explain the lower sales of combinations of penicillins (J01CR) and ceph-alosporins (J01DB-DE).
Beta-lactamase sensitive penicillins (J01CE) and tetra-cyclines (J01AA) were the most commonly sold antibiotics in 2018, measured as DDD per 1 000 inhabitants per day.
FIGURE 1�4� Sales of antibiotics in outpatient care, to humans, all genders, ATC-5, 2014-2018, prescriptions/1 000 inhabitants per year.
Pre
scrip
tions
/100
0 in
habi
tant
s pe
r ye
ar
2014
2015 2016 2017 2018
0
20
40
60
80
100
J01A
A - T
etra
cycli
nes
J01C
A - P
enici
llins w
ith e
xten
ded
spec
trum
exc
l. J01
CA08
J01C
A08
- Pivm
ecilli
nam
J01C
E - B
eta-l
acta
mas
e
sens
itive
penic
illins
J01C
F - B
eta-l
acta
mas
e
resis
tant
pen
icillin
s
J01C
R - C
ombin
ation
s
of p
enici
llins
J01D
B - J
01DE
-
Ceph
alosp
orins
J01E
A - T
rimet
hopr
im
J01E
E - T
rimet
hopr
im
with
sulph
onam
ides
J01F
A - M
acro
lides
J01F
F - L
incos
amide
s
J01M
A - F
luoro
quino
lones
J01X
E - N
itrof
uran
toin
J01X
X - O
ther
antib
acte
rials
10
30
50
70
90
Blad1
Sales of antibiotics (J01 excl. methenamine) to humans, all genders, per age, 1987-2018, prescriptions/1 000 inhabitants and year.
19871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018
0 - 4 years9461107101611221129132812691098938853824913842806787765716651650668697657547542482484392383349364338320
5 - 14 years378509456477489578549553518434430466416390412381339280286319338324285288295288242221214219206198
15 - 64 years391432422427441478474462428397382409397385392375367356365373379360332330331318292279273266260248
65 years and older376426429451490553578569535569573613674658661653658654660660656627592580572556534514513498496484
All ages418.9390400543479.9882427108463.5105016076481.0249936287500.6515700778560.2845700068556.3432348976535.5792852443492.4140152785461.5604154402448.8461059198481.2584239994472.0078604705462.9437745121468.5087751689450.3856045171437.0230006572418.1779187515425.5647740105436.112638808443.8209083756423.091134232391.9013623841390.2579062214385.3426823867373.9303195082342.6907354446327.9967322.7595317.6549308.9380295.8513
0 - 4 years19871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018946.080118066984821106.72075634002181016.11694225520991121.50242604679421128.85955845326131328.11599835008811269.00646803096151097.991663010813937.61216157540468852.9586017286058823.5797566592322912.81926669906591841.61381971523701806.32195188557705787.34301627170498765.32745898671897715.98857511043298650.72554484590398649.54341190959701668.03533832314201696.88031011562998656.50241288394398547.18221467386195542.426243383155482.16943046131303483.928448681546392.39656684385699383.215403985016348.62887888016405363.97040009006889338.12753228002799319.96996897236755 - 14 years19871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018378.32989646305901509.11575532320131455.54189911463914477.07363664226602488.67737623404531578.1455877111589549.13656361296501552.77070420340738517.790745860274434.29300591019933430.34502020388584466.48267483625602415.50817297637383389.84957108758903412.161493945171381.22194093986502338.64903003760099279.58962937703802285.82643532967899319.21280007816398337.57728996223699323.746492619251285.08285094786299287.73795968917898294.76430239709902288.24634846459998241.63806155588699221.22667236444801214.45591305393324219.02336582885692205.75315326306099197.7305675761110115 - 64 years19871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018391.23130562946585432.28373461757081422.08847722080344426.98316376829814441.33948680911175477.74074038611104474.24282653595367461.92105677715551427.98998361301415396.8258254598403381.76041681073264408.80502031659591396.69955421505648385.16637752079799391.69464930475903375.24494991913002366.78465205240002356.27236126377102364.74636143912102372.82919697872097379.40447989906102359.93217721644498331.56139270875099329.590229462911330.590763024946317.703854991816291.686008799246278.66031094794499273.17853507828926265.87245077988126259.857203631853247.5949133931458265 years and older19871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018376.13851924943231425.65786961005233429.0647223690641451.18411746054977489.76852173525452552.920891501347577.76107356647663568.52578639618287534.74700191438353569.16995022475999573.46274204977237612.5759570080254674.14306054083045658.26414060180502660.79664926281305653.15156546984997658.20921309562198653.84226091221797659.76253510343702660.09210560778604655.70680336934095627.18157587634505591.51433880763295579.540649062532572.221780910706556.02778780142899534.14433104721797514.318662412864513.16859778219703497.58862217912963496.47293658570197483.63678416226929All ages19871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018418.93904005431335479.98824271076597463.51050160764714481.02499362865194500.65157007783455560.28457000679248556.34323489757753535.57928524427132492.41401527848438461.56041544024703448.84610591984853481.25842399941763472.00786047054845462.94377451213802468.50877516888801450.38560451707502437.023000657213418.17791875146901425.56477401049699436.11263880796002443.82090837556802423.09113423203701391.90136238410298390.25790622140897385.34268238672701373.93031950820699342.69073544461003327.99674521071501322.75945628326866317.65491826884477308.93804226908799295.85132450390017
Prescriptions/1 000 inhabitants and year
helenerikssonFile AttachmentFig 1.3 Antibiotic_Prescr per TIN and age group_1987-2018.xlsx
Blad1
Sales of antibiotics to humans, all genders, ATC5, 2014-2018, prescriptions/1 000 inhabitants and year.
20142015201620172018
J01AA - Tetracyclines4039363531
J01CA - Penicillins with extended spectrum excl. J01CA081919181817
J01CA08 - Pivmecillinam3434343333
J01CE - Beta-lactamase sensitive penicillins9392939184
J01CF - Beta-lactamase resistant penicillins3837373637
J01CR - Combinations of penicillins66677
J01DB - J01DE - Cephalosporins1010965
J01EA - Trimethoprim76555
J01EE - Trimethoprim with sulphonamides77778
J01FA - Macrolides99998
J01FF - Lincosamides1515151414
J01MA - Fluoroquinolones2323222120
J01XE - Nitrofurantoin2525252626
J01XX - Other antibacterials1413131212
2014 J01AA - TetracyclinesJ01CA - Penicillins with extended spectrum excl. J01CA08 J01CA08 - Pivmecillinam J01CE - Beta-lactamase sensitive penicillins J01CF - Beta-lactamase resistant penicillins J01CR - Combinations of penicillinsJ01DB - J01DE - Cephalosporins J01EA - Trimethoprim J01EE - Trimethoprim with sulphonamides J01FA - Macrolides J01FF - Lincosamides J01MA - Fluoroquinolones J01XE - Nitrofurantoin J01XX - Other antibacterials39.83373949077975619.27782496466512933.979120908288693.0744072700247538.4645133409864576.09194696783697519.79111784261551147.19543582988832236.79128290455935979.209046389871334214.94577839563108423.2839986131478925.1417749384542913.5505280323289162015 J01AA - TetracyclinesJ01CA - Penicillins with extended spectrum excl. J01CA08 J01CA08 - Pivmecillinam J01CE - Beta-lactamase sensitive penicillins J01CF - Beta-lactamase resistant penicillins J01CR - Combinations of penicillinsJ01DB - J01DE - Cephalosporins J01EA - Trimethoprim J01EE - Trimethoprim with sulphonamides J01FA - Macrolides J01FF - Lincosamides J01MA - Fluoroquinolones J01XE - Nitrofurantoin J01XX - Other antibacterials38.73337946550628219.03972923936800833.73120195170895492.07595291235416837.4047113293811516.19203876333630999.57634147930387416.37219019928996126.78091646400485098.982334181939613414.84135952778984622.92293652996120625.22540730280163113.3643434552245192016 J01AA - TetracyclinesJ01CA - Penicillins with extended spectrum excl. J01CA08 J01CA08 - Pivmecillinam J01CE - Beta-lactamase sensitive penicillins J01CF - Beta-lactamase resistant penicillins J01CR - Combinations of penicillinsJ01DB - J01DE - Cephalosporins J01EA - Trimethoprim J01EE - Trimethoprim with sulphonamides J01FA - Macrolides J01FF - Lincosamides J01MA - Fluoroquinolones J01XE - Nitrofurantoin J01XX - Other antibacterials35.57439805453589118.22695057779313333.83467920114237993.21707596281683536.7304208286311966.47049944183427969.40440971729111835.35000599430495346.85289650804581918.911262664555344814.76365333650322722.11081353326260825.32073591995628412.8791778554437572017 J01AA - TetracyclinesJ01CA - Penicillins with extended spectrum excl. J01CA08 J01CA08 - Pivmecillinam J01CE - Beta-lactamase sensitive penicillins J01CF - Beta-lactamase resistant penicillins J01CR - Combinations of penicillinsJ01DB - J01DE - Cephalosporins J01EA - Trimethoprim J01EE - Trimethoprim with sulphonamides J01FA - Macrolides J01FF - Lincosamides J01MA - Fluoroquinolones J01XE - Nitrofurantoin J01XX - Other antibacterials34.59016585338913817.68827350616844333.32475250754040390.76739495633533736.043470270039897.0218034681410085.54568799497116244.98061410365604217.43760500714696449.184251606753793614.47501604027472121.2032772284726425.85973421317312711.8954657322404172018 J01AA - TetracyclinesJ01CA - Penicillins with extended spectrum excl. J01CA08 J01CA08 - Pivmecillinam J01CE - Beta-lactamase se